Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients

American Journal of Clinical Dermatology

Volumn 5, Issue 3, 2004, Pages 161-168

  Stratigos, Alexander J ^a   Katsambas, Andreas D ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ANDREAS SYGROS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYACID; 4 S CYSTEAMINYLPHENOL; AMIODARONE; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; AZELAIC ACID; BLEACHING AGENT; CHLOROQUINE; CHLORPROMAZINE; CLOFAZIMINE; CORTICOSTEROID; DAPSONE; DEPIGMENTING AGENT; DEXAMETHASONE; DICARBOXYLIC ACID; FUROCOUMARIN; GLYCOLIC ACID; HYDROCORTISONE; HYDROQUINONE; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; KOJIC ACID; MINOCYCLINE; MONOPHENOL MONOOXYGENASE; PHENOL DERIVATIVE; RETINOIC ACID; RETINOID; TETRACYCLINE; TRICHLOROACETIC ACID; UNINDEXED DRUG;

ACNE VULGARIS; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; ERYTHEMA; HUMAN; HYPERPIGMENTATION; IRRITANT DERMATITIS; LOTION; LOW LEVEL LASER THERAPY; MELANOSIS; PHOTODERMATOSIS; PIGMENTATION; PRIORITY JOURNAL; PUSTULOSIS PALMOPLANTARIS; REVIEW; SIDE EFFECT; SKIN CARE; SKIN DEFECT; SKIN INFLAMMATION; SKIN PIGMENTATION; TOOTH COLOR;

HUMANS; HYPERPIGMENTATION; MELANOSIS; SKIN PIGMENTATION;

EID: 3142619391     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200405030-00004     Document Type: Review

References (49)

1. Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic disease. J Am Acad Dermatol 2002; 46 (Suppl.2): S41-62
2. O'Brien TJ, Dyall-Smith D, Hall AP. Melasma of the forearms. Austral J Dermatol 1997; 38: 35-7
3. Grimes PE. Melasma: etiologic and therapeutic considerations. Arch Dermatol 1995; 131: 1453-7
4. Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol 1981; 4: 698-710
5. Taylor SC. Epidemiology of skin diseases in ethnic populations. Dermatol Clin 2003; 21 (4): 601-7
6. Kimbrough-Green CK, Griffiths CEM, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in Black patients: a vehicle-controlled clinical trial. Arch Dermatol 1994; 130: 727-33
7. Resnik S. Melasma induced by oral contraceptive drugs. JAMA 1967; 199: 95-9
8. Johnston GA, Sviland L, McLelland J. Melasma of the arms associated with hormone replacement therapy [letter]. Br J Dermatol 1998; 139; 932
9. Hassan I, Kaur I, Sialy R, et al. Hormonal milieu in the maintenance of melasma in fertile women. J Dermatol 1998; 25: 510-2
10. Katsambas AD, Stratigos AJ. Depigmenting and bleaching agents: coping with hyperpigmentation. Clin Dermatol 2001; 19: 483-8
11. Kramer KE, Lopez A, Stefanato CM, et al. Exogenous ochronosis. J Am Acad Dermatol 2000; 42: 869-71
12. Levin CY, Maibach H. Exogenous ochronosis: an update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001; 2: 213-7
13. Perez-Bernal A, Munoz-Perez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol 2000; 1 (5): 261-8
14. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975; 111: 40-8
15. Kang WH, Chun SC, Lee S. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoin acid, hydroquinone and hydrocortisone): clinical and histoiogical studies. J Dermatol 1998; 25: 587-96
16. Yoshimura K, Harii K, Aoyama T, et al. A new bleaching protocol for hyperpigmented skin lesions with a high concentration of all-trans-retinoic acid aqueous gel. Aesthetic Plast Surg 1999; 23: 285-91
17. Tadaki T, Watanabe M, Kumasaka K, et al. The effect of topical tretinoin on the photodamaged skin of Japanese. Tohoku J Exp Med 1993; 169: 131-9
18. Griffiths CEM, Finkel LJ, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma: a vehicle-controlled, clinical trial. Br J Dermatol 1993; 129: 415-21
19. Balina LM, Graupe K. The treatment of melasma: 20% azelaic acid versus 4% hydroquinone cream. Im J Dermatol 1991; 30: 893-5
20. Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl. (Stockh) 1989; 143: 58-61
21. Garcia A, Fulton JE. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg 1999; 22: 443-7
22. Jimbow K. N-acetyl-4-5cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma. Arch Dermatol 1991; 127: 1528-34
23. Lim JTE, Tham SN. Glycolic acid peels in the treatment of melasma among Asian women. Dermatol Surg 1997; 23: 177-9
24. Sarkar R, Kaur C, Bhalla M, et al. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg 2002; 28: 828-32
25. Hurley ME, Guevara IL, Gonzales RM, et al. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol 2002; 138: 1578-82
26. Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg 1999; 25: 18-22
27. Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched laser. J Dermatol Surg Oncol 1994; 20: 592-7
28. Manaloto RM, Alster T. Erbium: YAG laser resurfacing for refractory melasma. Dermatol Surg 1999; 25: 121-3
29. Noun K, Bowes L, Chartier T, et al. Combination treatment of melasma with pulsed CO2 laser followed by Q-switched alexandrite laser: a pilot study. Dermatol Surg 1999; 25: 494-7
30. Nordlund JJ. Postinflammatory hyperpigmentation. Dermatol Clin 1988; 6: 185-92
31. Ruiz-Maldonado R, Orozco-Covarrubias ML. Postinflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg 1997 Mar; 16 (1): 36-43
32. Bulengo-Ransby SM, Griffiths CEM, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in Black patients. N Engl J Med 1993; 328: 1438-43
33. Burns RL, Prevost-Blank PL, Lawry MA, et al. Glycolic acid peels for postinflammatory hyperpigmentation in Black patients. Dermatol Surg 1997; 23: 171-5
34. Watanabe S, Brorson S, Dalickas G, et al. Comparative studies of femtosecond to microsecond laser pulses on selective pigmented cell injury in skin. Photochem Photobiol 1991; 53: 757-62
35. Dereure O. Drug-induced skin pigmentation: epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001; 2: 253-63
36. Basler R. Minocycline-related hyperpigmentation. Arch Dermatol 1985; 121: 606-8
37. Argenyi ZB, Finelli L, Bergfeld WF, et al. Minocycline-related cutaneous hyperpigmentation as demonstrated by light microscopy, electron microscopy and X-Ray energy spectroscopy. J Cutan Pathol 1987; 14: 176-80
38. Odom RB, James WD, Berger TG. Contact dermatitis and drug eruptions. In: Odom RB, James WD, Berger TG, et al., editors. Andrew's diseases of the skin: clinical dermatology. 9th ed. Philadephia (PA): WB Saunders Co., 2000: 133-4
39. Sokol RJ, Lichtenstein PK, Farrell MK. Quinacrine hydrochloride-induced yellow discoloration of the skin in children. Pediatrics 1982; 69 (2): 232-3
40. Waitzer S, Butany J, From L, et al. Cutaneous ultrastructural changes and photosensitivity associated with amiodarone therapy. J Am Acad Dermatol 1987; 16 (4): 779-87
41. Job CK, Yoder L, Jacobson RR, et al. Skin pigmentation from clofazimine therapy in leprosy patients: a reappraisal. J Am Acad Dermatol 1990; 23 (2): 236-41
42. Collins P, Cotterill JA. Minocycline-induced pigmentation resolves after treatment with the Q-switched ruby laser. Br J Dermatol 1996; 135: 317-9
43. Tsao H, Busam K, Barnhill RL, et al. Treatment of minocycline-induced hyperpigmentation with the Q-switched ruby laser. Arch Dermatol 1996; 132: 1250-1
44. Becker-Wegerich PM, Kuhn A, Malek L, et al. Treatment of nonmelanotic hyperpigmentation with the Q-switched ruby laser. J Am Acad Dermatol 2000; 43: 272-4
45. Karrer S, Hohenleutner U, Szeimies RM, et al. Amiodarone-induced pigmentation resolves after treatment with the Q-switched ruby laser. Arch Dermatol 1999; 135: 251-3
46. Ramirez CO. The ashy dermatosis (erythema dyschromicum perstan: epidemiological study and report of 139 cases. Cutis 1967; 3: 244-7
47. Ing EB, Buncic JR, Weiser BA, et al. Periorbital hyperpigmentation and erythema dischromicum perstans. Can J Ophthalmol 1992; 27: 353-5
48. Baranda L, Torres-Alvarez B, Cortes-Franco R, et al. Involvement of cell adhesions and activation molecules in the pathogenesis of erythema dischromicum perstans (ashy dermatitis): the effect of clofazimine therapy. Arch Dermatol 1997; 133: 325-9
49. Kontochristopoulos G, Stavropoulos P, Panteleos D, et al. Erythema dischromicum perstans: response to dapsone therapy. Int J Dermatol 1998; 37: 790-9